A 4 week study with BI 144807 in patients >= 50 years with wet age related macular degeneratio
- Conditions
- patients with newly diagnosed, unilateral, wet Are-Related Macular DegenerationMedDRA version: 17.0Level: LLTClassification code 10067791Term: Wet macular degenerationSystem Organ Class: 100000004853Therapeutic area: Diseases [C] - Eye Diseases [C11]
- Registration Number
- EUCTR2013-004567-30-HU
- Lead Sponsor
- Boehringer Ingelheim RCV GmbH & Co KG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Newly diagnosed men and women with unilateral subfoveal choroideal neovascularization secondary to age-related macular degeneration
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 10
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 50
Exclusion Criteria
Additional eye disease that could compromizse best corrected visual acuity, such as uncontrolled glaucoma
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does BI 144807 target in wet age-related macular degeneration (wAMD) pathophysiology?
How does BI 144807's pharmacodynamic profile compare to standard anti-VEGF therapies for newly diagnosed wAMD?
Which biomarkers correlate with treatment response in EUCTR2013-004567-30-HU's Boehringer Ingelheim wAMD trial?
What adverse events were reported in Boehringer Ingelheim's 4-week BI 144807 monotherapy trial for wAMD patients?
Are there combination therapies involving BI 144807 and corticosteroids for unilateral wAMD treatment efficacy?